Probmet Therapeutics
An oncology therapeutics company developing new targeted treatments for breast cancer brain metastatic patients.
An oncology therapeutics company developing new targeted treatments for breast cancer brain metastatic patients.
Probmet is a precision oncology therapeutics company that is focused on developing targeted treatments for breast cancer brain metastatic patients. Founded in 2022 and headquartered in Denmark, Probmet aims to address the limited treatment options available for metastatic breast cancer in the brain. The company's slogan, "An oncology therapeutics company developing new targeted treatments for breast cancer brain metastatic patients" emphasizes its commitment to providing innovative solutions for this devastating disease.
The most recent funding round for Probmet involved a €500.00KConvertible Note investment on 15 March 2022, with the BioInnovation Institute participating as the investor. This investment signifies confidence in Probmet's potential to significantly impact the field of oncology therapeutics, particularly in the treatment of metastatic breast cancer in the brain.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | €500.00K | 1 |
|
15 Mar 2022 |
No recent news or press coverage available for Probmet Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
